Physician profile
Thomas Hong
NPI 1437253150
$1,053.48
in general payments reported to CMS, 2019-2025
11 companies · $663 in 2025
The $663 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2021: $51.46 · 2023: $47.40 · 2024: $151 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $569.16 | 2023-2025 | Carto 3 |
| Abbvie INC. | $199.45 | 2021-2025 | |
| Pfizer INC. | $61.85 | 2019-2024 | |
| Lilly USA, LLC | $43.30 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.50 | 2019 | |
| Novo Nordisk INC | $36.52 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $24.76 | 2025 | Shingrix |
| Gilead Sciences, INC. | $24.33 | 2024 | |
| Sanofi Pasteur INC. | $18.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.28 | 2019 | |
| Merck Sharp & Dohme LLC | $15.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.